NCT07772531Not yet recruitingPhase 2
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 14 Aug 2026
- Start date
- 30 Oct 2026
- Primary completion date
- 6 Nov 2028
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Depression
- NCT number
- NCT07772531
- EudraCT number
- 2026-526617-28
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 200
- From 30 Oct 2026 to the primary completion date, 6 Nov 2028
- 27 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation.
Other illness
- Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode.
- Participants must not have recent history of active suicidal ideation or attempt within the past year.
- Participants must not have recent history of alcohol/substance abuse or use of cannabis.
- Participants must not have significant ECG abnormalities, or poorly controlled diabetes.
Other
- Other protocol defined inclusion/exclusion criteria apply.
Who the study is looking for
- Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview.
- Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale.
- Participant must have current MDE duration \>12 weeks at screening.
- Outpatient participants able to comply with study procedures.
- Participant require medication washout completed before baseline.
- Participant must have BMI within protocol range.
- Participants must meet reproductive safety requirements.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (27)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.